Rocket Pharmaceuticals

We’re honored to receive the 2026 @BioTech_Awards for Functional Genomics Innovation of the Year, recognizing the scientific work behind the first-ever FDA approved therapy for severe Leukocyte Adhesion Deficiency-I (LAD-I).

Thank you to BioTech Breakthrough for this recognition, and to the patients, families, clinicians and #TeamRocket members who made this milestone possible.

November is #NationalFamilyCaregiversMonth. #TeamRocket is honoring the caregivers supporting loved ones living with rare diseases. Thank you for all you do!

We're committed to advancing #GeneticMedicine for the patients & families who need it most.

At last week’s Meeting on the Mesa, our CEO Gaurav Shah, MD, joined fellow industry leaders to share lessons in clinical safety, manufacturing and patient access, and discuss how those lessons can strengthen the path from development to treatment.

Thank you to the @alliancerm and our fellow panelists for sharing their experience and perspectives. At Rocket, our purpose remains clear: translate scientific progress into meaningful treatment options for patients and families who need them.

#CGMesa26 #GeneticMedicines

October is #SuddenCardiacArrestAwarenessMonth. Sudden cardiac arrest can affect anyone, but genetic heart conditions like PKP2-associated arrhythmogenic cardiomyopathy (PKP2-ACM) and BAG3-associated dilated cardiomyopathy (BAG3-DCM) can put some individuals at greater risk.

That's why Rocket remains committed to advancing #GeneticMedicine for #CardiovascularDisease.